Respiratory syncytial virus infection in hospitalized children older than 2 years with community-acquired pneumonia

Almasri M1,2, Papa A1, Souliou E1, Haidopoulou K3, Eboriadou M3

1Department of Microbiology of Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece
2Biology and Biotechnology Department of Science Faculty, An Najah National University of Nablus, Nablus, West Bank, Palestinian Authority
3Fourth Department of Paediatrics of Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

Abstract

**Background/aim:** Respiratory syncytial virus (RSV) is one of the main causes of bronchiolitis and pneumonia in infants and young children. The aims of the present study were to evaluate the role of RSV in children >2 years old hospitalized with community-acquired pneumonia (CAP) and to type the circulating RSV strains.

**Materials and Methods:** Serum and throat swab samples were taken upon admission from Greek children aged > 2 years, hospitalized with atypical CAP, and when possible, a second serum sample was also taken. RSV IgG and IgM antibodies were determined by Enzyme Linked Immunosorbent Assay (ELISA), while throat swab samples were tested by nested RT-PCR. Additional serological testing was performed to find out probable co-infections.

**Results:** A total of 101 children with atypical CAP were included in the study, aged 2.5-14 years (median 8.25). RSV IgM antibodies were detected in 21 (20.7%) cases, either in the first or/and in the second serum sample, while RSV genome was detected in 11 out of 15 (73%) IgM-positive patients, which were further tested by PCR. PCR-positive results were obtained up to the 7th day of illness. Among the 11 cases, one was of type B, and all the rest were of type A. The median age of the RSV-positive children was 4 years (range 3-13 years). Although RSV was detected in all seasons, the majority of cases (31%) were detected in winter. Co-infection was detected in 3 cases (two with *Mycoplasma pneumoniae* and one with adenovirus).

**Conclusions:** Apart from the known role of RSV as the most important pathogen causing acute respiratory disease in infants and young children, it is also a significant viral pathogen in older children hospitalized because of CAP. Genetic typing provides further insight into the epidemiology of the disease. Hippokratia 2013, 17, 2: 146-149

**Keywords:** Respiratory syncytial virus, community-acquired infection, pneumonia, genotypes, children, Greece

**Corresponding Author:** Dr Almasri Motasem, Biology and Biotechnology Department of Science Faculty, An Najah National University of Nablus, Nablus, P.O. BOX: 7, West Bank, Palestinian Authority, tel: +97092342593, mob: +970599107285, e-mail: motasim25@hotmail.com

Introduction

Community-acquired pneumonia (CAP) is a common respiratory illness among patients of all ages. Especially among children, CAP is a significant cause for morbidity, and it is caused mainly by viral pathogens, often by more than one, since co-infections occur in approximately 30% of cases1. Although the knowledge on the prevalence of viral infections in children with CAP is limited, respiratory syncytial virus (RSV) is usually the most frequently detected virus followed by rhinoviruses and human bocavirus2,3. In general, RSV is well recognized as the most important pathogen causing acute respiratory disease in infants and young children, mainly in the form of bronchiolitis and pneumonia3.

Two antigenic RSV subtypes (A and B) are known, with low-scale cross protection1. It is unclear why some children experience severe RSV disease and others develop milder disease. It may be due to host factors, maternal immunity, or differences in the virus itself. Genotypes show complex circulation patterns probably facilitated by herd immunity to certain genotypes which might influence disease severity3.

Given the development of large-throughput screening techniques and improvement of clinical data management, there is increasing potential for studies to identify the cause of the disease to inform diagnostic and therapeutic decision making4. In addition, the new diagnostic techniques are used to evaluate the epidemiology of respiratory tract infections utilizing specimens obtained prospectively1 and/or retrospectively2. In a recent study carried in children (<14 years) with CAP, RSV was the most frequently detected virus1. The aims of the present study were to investigate the role of RSV in Greek children older than 2 years hospitalized with CAP, to determine the type of the virus strain and to find out any relation with the severity of the disease.
Materials

During a 13-month period (May 2003 to May 2004) serum and throat swab samples were collected prospectively from Greek children older than 2 years, hospitalized with CAP in the Fourth Department of Paediatrics, in the University General Hospital AHEPA in Thessaloniki (Northern Greece). The present study included only children with symptoms, signs and/or chest radiography findings consistent with atypical pneumonia. In atypical pneumonia, X-ray showed hilar adenopathy and unilateral or bilateral infiltrates, and/or patient looking worse than the symptoms suggest, and/or not showing response to treatment with β-lactam antibiotics. Patients were excluded from the study when there was evidence of bacterial infection or chronic respiratory illness, and those with other underlying diseases that might predispose patients to pneumonia.

On patient’s admission, pediatricians were completing a questionnaire regarding the age of the patient, the date of onset of the disease, the clinical symptoms (malaise, fever ≥ 38°C, tachypnea, cough, sputum production, abdominal complains), the laboratory findings, and the potential presence of underlying disease. Diagnosis of pneumonia was based on the presence of new infiltrates on chest radiography (single or multiple infiltrates, opacities or consolidations), symptoms (like chills and chest pain), and physical examination findings (rales or crackles, wheezes on auscultation of bronchial breathing). All children included in the study were hospitalized for at least 2 days.

A serum and a throat swab specimens were taken upon patient’s admission, while a second serum sample was taken 9-24 days after onset of the illness (when possible). The throat swab specimen (viscose swab) was placed in 2 ml of transport medium. All specimens were stored at -20°C. The serial serum samples were serologically tested at the same run.

The study protocol was approved by the Ethics Committee of the hospital, while informed parental consent was obtained for each patient.

Methods

Serology

Serum RSV IgG and IgM antibodies were determined using ELISA (Virion/Serion, Germany), following the manufacturer’s instructions. Serologic diagnosis of infection was established when IgM was above the cut off value, or a fourfold increase in the IgG antibody titers in paired serum specimens was observed.

All sera were additionally tested for IgM and IgG antibodies against Mycoplasma pneumoniae, Chlamydia pneumoniae, Coxiella burnetii, adenovirus, influenza virus types A and B, and parainfluenza virus types 1, 2, and 3.

RNA extraction and PCR

Molecular methods were applied on throat swab specimens from the RSV IgM-positive and few RSV IgM-negative patients for whom an acute throat swab sample was available. RNA was extracted by a boiling method according to Waring et al., and a nested RT-PCR, which amplifies a partial fragment of the RSV fusion protein was performed. PCR products were detected by 1.5% agarose gel electrophoresis with ethidium bromide staining.

Hematologic tests

For each patient white blood cells (WBC) count was measured in an automated cell counter and the erythrocyte sedimentation rate (ESR) was measured in a period of one hour; C-reactive protein (CRP) was estimated by nephelometry (Image Beckmann). ESR <10 mm/hour and CRP < 0.5 mg/dl were considered at normal levels, while normal WBC range in the various age groups was considered according to Camitta.

Statistical analysis

IBM SPSS version 19.0 for Windows was used: Fisher’s exact test was applied for comparison of the prevalence of RSV infection among seasons; chi-square test and Fisher’s exact test was used for comparison of the clinical and laboratory parameters between groups; chi-square test was used for comparison of the prevalence of RSV infection in different age groups; and independent t-test for comparison of the mean values among groups. A p-value <0.05 was considered significant.

Results

The present study included 101 children older than 2 years (2.5-14 years, median 8.25) hospitalized with CAP. RSV IgM antibodies were detected in 21 (20.7%) children, with 3 of them presenting also a fourfold increase in the RSV IgG antibodies in the two serial serum samples. Among the 21 patients with RSV infection, 9 were males and 12 females (p=0.129). The median age of the children with and without RSV infection was 4 and 5 years, respectively. The frequency of RSV infection among children 2-5 years (21%) did not differ from that among children 6-14 years (20.5%) (p=0.941). Figure 1 shows the seasonal distribution of RSV infection in children during one year.

![Figure 1: Seasonal distribution of RSV infection in children during one year.](image)
children during one year. Cases were detected during all seasons of the year; although they were more frequent during winter (31%), the seasonal differences were not statistically significant.

Fever and cough were the most common symptoms in patients with RSV infection (both 95%), while increased ESR and CRP levels were the most common laboratory findings (both 90%). The frequency of clinical and laboratory findings among patients with RSV infection did not differ significantly from those with non-RSV infection. In Table 1 are shown the means of temperature, WBC count, percentage of neutrophils and lymphocytes, ESR and CRP in the patients with and without RSV infection; no significant difference was observed between the two groups.

Molecular methods were applied in 15 of the RSV IgM-positive patients; 6 IgM-negative patients with very acute disease (1st day of illness) were also tested. RSV RNA was detected in 11 of 15 (73%) patients, while all 6 IgM-negative children were tested negative. RSV type A was detected in 10 cases, and type B in one case.

Among the other pathogens tested, *Mycoplasma pneumoniae* was detected in 22% of the cases, *Chlamydia pneumoniae* in 8%, *Coxiella burnetii* in 3%, influenza virus types A and B in 4% each, parainfluenzaviruses (types 1,2,3) in 3% and adenovirus in 3%. Co-infections were detected in 3 RSV cases, two with *Mycoplasma pneumoniae* and one with adenovirus.

**Discussion**

In the present study, 21 among 101 (20.7%) Greek children older than 2 years hospitalized because of CAP, were diagnosed with RSV infection. Similar results (17%) were reported in a previous study in which the diagnosis was also based on serology. A higher rate (52.7%) was reported in another study in which real-time PCR was used; however in that study the children were less than 5 years old and they were hospitalized with various respiratory tract infections (not only CAP).  

In temperate climate, RSV activity increases in the winter months. In the present study, during winter (31%), the seasonal differences were not statistically significant. Fever and cough were the most common symptoms in patients with RSV infection (both 95%), while increased ESR and CRP levels were the most common laboratory findings (both 90%). The frequency of clinical and laboratory findings among patients with RSV infection did not differ significantly from those with non-RSV infection. In Table 1 are shown the means of temperature, WBC count, percentage of neutrophils and lymphocytes, ESR and CRP in the patients with and without RSV infection; no significant difference was observed between the two groups.

Molecular methods were applied in 15 of the RSV IgM-positive patients; 6 IgM-negative patients with very acute disease (1st day of illness) were also tested. RSV RNA was detected in 11 of 15 (73%) patients, while all 6 IgM-negative children were tested negative. RSV type A was detected in 10 cases, and type B in one case. Among the other pathogens tested, *Mycoplasma pneumoniae* was detected in 22% of the cases, *Chlamydia pneumoniae* in 8%, *Coxiella burnetii* in 3%, influenza virus types A and B in 4% each, parainfluenzaviruses (types 1,2,3) in 3% and adenovirus in 3%. Co-infections were detected in 3 RSV cases, two with *Mycoplasma pneumoniae* and one with adenovirus.

**Table 1:** Mean values of various clinical and laboratory parameters in pediatric CAP patients older than 2 years with and without RSV infection.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Children with CAP (N=101) Mean value ±SD</th>
<th>Non-RSV Infection</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n=21</td>
<td>n= 80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Temperature (°C)</td>
<td>39 ± 0.91</td>
<td>39 ± 1.04</td>
<td>0.733</td>
</tr>
<tr>
<td>WBC (Cell/mm³)</td>
<td>16190 ± 8597.48</td>
<td>15543 ± 7645.41</td>
<td>0.744</td>
</tr>
<tr>
<td>Neutrophils %</td>
<td>69.73 ± 17.89</td>
<td>71.59 ± 14.93</td>
<td>0.645</td>
</tr>
<tr>
<td>Lymphocytes %</td>
<td>22.65 ± 16.55</td>
<td>21.89 ± 14.22</td>
<td>0.840</td>
</tr>
<tr>
<td>ESR (mm/hour)</td>
<td>64 ± 33.14</td>
<td>70 ± 30.67</td>
<td>0.439</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>6.1 ± 5.24</td>
<td>8.4 ± 8.01</td>
<td>0.234</td>
</tr>
</tbody>
</table>

Variations in RSV detection rates and the predominant types are not unexpected, due to differences in inclusion criteria, applied diagnostic methods, and probable community outbreaks during the study period. Inter-country differences are also expected due to the diversity of the climatic conditions and the human activities. RSV genotyping has never been performed previously in Northern Greece, thus, the present study can serve as threshold for future studies. It was found that RSV type A and B co-circulated in 2003, with clear predominance of type A, while in 2004 only type A was detected. In a study in UK during 1995–96, RSV type A and B co-circulated, after which RSV B was not detected; in 1996–97 and 1997–98, RSV types A and B co-circulated, and in each of the three winters, RSV type A was the predominant circulating type. It seems that there are continuous changes in the predominant RSV subtypes. Such data and continuous monitoring of the circulating RSV strains provide important information for the epidemiology of the disease and for vaccine development.

The present study shows the limitation of the clinical and laboratory findings for the diagnosis of RSV infection in CAP cases. The presence of high fever and cough in 95% of our cases and the increased ESR and CRP in 90% of the patients are suggestive of severe form of the disease. Since only one of the cases was caused by RSV type B, any relation with the severity of the disease was not possible. However, a previous study in Greece showed that RSV-A-induced bronchiolitis was more severe than RSV-B-induced one, in agreement with the majority of previously published studies.
During the study period, *M. pneumoniae* was the most often (22%) detected pathogen, followed by RSV (21%). Woodhead et al.\textsuperscript{23} reported that *Chlamydia pneumoniae* was the most frequent (17%) causative pathogen of CAP in Europe. RSV co-infection was detected in 3 cases (two with *M. pneumoniae* and one with adenovirus). RSV in mixed infections has been often reported in previous studies\textsuperscript{23}. The detection of mixed infections is important for the proper treatment of the patients. In a recent study in Greece it was shown that viral co-infections were associated with increased probability for hospitalization\textsuperscript{24}.

In conclusion, RSV was detected in 20.7% of pediatric CAP patients older than 2 years, suggesting that its role in older children has not to be underestimated. Concerning RSV subtyping, type A predominated during the study period; further studies are needed to get a better insight into the circulation patterns of the RSV types and find out their probable relation with disease severity.

**Conflict of interest**

There is no conflict of interest.

**Acknowledgment**

Dr Motasem Almasri was supported by a grant from the State Scholarships Foundation (IKY), Greece.

**References**